{"entity":{"id":"nct06953999","kind":"trial","name":"A Phase III Study of Ivonescimab + Chemo With/Without AK117 in Metastatic Pancreatic Cancer","aka":[],"tldr":"A phase 3 trial of Gemcitabine and Ivonescimab in pancreatic ductal adenocarcinoma, run by Akeso, now recruiting.","summary":"A Phase III Study of Ivonescimab + Chemo With/Without AK117 in Metastatic Pancreatic Cancer is a phase 3 interventional study registered as NCT06953999 by Akeso, with 999 participants planned, started 2025-06-11 and due to reach its primary completion in 2027-05-14. Interventions recorded: Ivonescimab, AK117, Albumin-bound Paclitaxel, Gemcitabine, Ivonescimab, AK117 Placebo, Albumin-bound Paclitaxel, Gemcitabine and Ivonescimab Placebo, AK117 Placebo, Albumin-bound Paclitaxel, Gemcitabine.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT06953999","url":"https://clinicaltrials.gov/study/NCT06953999"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["pancreatic","metastatic-pdac"],"sections":[],"technologies":["bispecific-antibody","checkpoint-inhibitor"],"targets":[],"drugs":["gemcitabine","ivonescimab"],"companies":["akeso"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT06953999","phase":"3","setting":"A Randomized, Controlled, Multi-center Phase III Clinical Study of Ivonescimab Plus Chemotherapy With or Without AK117 Versus Placebo Combined With Chemotherapy as First-line Treatment for Metastatic Pancreatic Cancer","sponsor":"Akeso","participation":[{"nct":"NCT06953999","source":"https://clinicaltrials.gov/study/NCT06953999","fetchedAt":"2026-10-07T16:55:19.231Z","studySha256":"2b5a3ec1b8e2c6f686b4ebf4c8f309cdf8d53f3ddae73ae17af04b5a33d586e1","overallStatus":"RECRUITING","lastUpdatePosted":"2026-03-04","leadSponsor":"Akeso","collaboratorCount":0,"minimumAge":"18 Years","maximumAge":"75 Years","sex":"ALL","healthyVolunteers":false,"hasEligibility":true,"enrolment":999,"enrolmentType":"ESTIMATED","siteCount":3,"recruitingSiteCount":3,"countries":["China"]}],"started":"2025-06-11","startedType":"actual","enrolled":999,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct06953999/","neighbours":{"cancer":[{"id":"metastatic-pdac","kind":"cancer","name":"Metastatic pancreatic ductal adenocarcinoma","route":"/cancers/metastatic-pdac/"},{"id":"pancreatic","kind":"cancer","name":"Pancreatic ductal adenocarcinoma","route":"/cancers/pancreatic/"}],"technology":[{"id":"bispecific-antibody","kind":"technology","name":"Bispecific antibodies","route":"/technologies/bispecific-antibody/"},{"id":"checkpoint-inhibitor","kind":"technology","name":"Immune checkpoint inhibitors","route":"/technologies/checkpoint-inhibitor/"}],"drug":[{"id":"gemcitabine","kind":"drug","name":"Gemcitabine","route":"/drugs/gemcitabine/"},{"id":"ivonescimab","kind":"drug","name":"Ivonescimab","route":"/drugs/ivonescimab/"}],"company":[{"id":"akeso","kind":"company","name":"Akeso","route":"/companies/akeso/"}]}}